Abbott gained a global sales and distribution license to Luminex' xTAG™ RVP (respiratory viral panel). Abbott has the exclusive rights to distribute the test outside the U.S. and semiexclusive rights in the U.S.
FDA cleared xTAG RVP in January 2008 and the technology became CE marked for sale in Europe in November 2006. In the U.S., xTAG RVP has been cleared to detect 12 viruses and viral subtypes: adenovirus, influenza A (all subtypes), influenza A H1, influenza A H3, influenza B, metapneumovirus, parainfluenza 1, 2, and 3, respiratory syncytial virus (RSV) A and B, as well as rhinovirus.
In Europe, xTAG RVP is certified to detect and identify 20 viruses and viral subtypes. These include all the targets approved in the U.S. plus corona virus 229E, HKU1, NL63, and OC43, enterovirus, influenza A H5, parainfluenza 4, and SARS.